Moderna Inc.
Moderna Appoints Abbas Hussain to Board of Directors
Summary
Moderna, Inc. announced on September 28, 2024, that Abbas Hussain has been appointed to its Board of Directors, effective October 2, 2024. Mr. Hussain, a seasoned healthcare executive, most recently served as Chief Executive Officer of Vifor Pharma and brings over 35 years of leadership experience in the industry. His appointment coincides with the Board's decision to fix its size at nine directors. Additionally, a press release on October 2, 2024, highlighted his extensive experience and the company's expectations for his contributions to its strategic direction.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement